Sign in

CIK 0001650664

  • Non-accelerated filer
  • Smaller reporting company

Editas Medicine, Inc.

Sign in to watch
Ticker
EDIT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
464097528
Phone
+1 617-401-9000
Business address
11 HURLEY ST., CAMBRIDGE, MA, 02141
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market sale Chief Technology Officer sold 3,000 shares at $24.50 ($73,500)
  3. 3 Insider Initial Statement of Ownership
  4. 4 Open-market buy Director bought 10,200 shares at $23.94 ($244,188)
  5. 4 Open-market sale Chief Technology Officer sold 3,000 shares at $20.42 ($61,260)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market sale Chief Financial Officer sold 6,895 shares at $21.39 ($147,484)
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market sale Chief Technology Officer sold 7,000 shares at an average $26.36 ($184,540)
  15. 4 Open-market sale President and CEO sold 12,000 shares at $25.27 ($303,240)
  16. 4 Open-market sale Chief Financial Officer sold 7,000 shares at $22.48 ($157,360)
  17. 4/A Exercise or conversion Chief Financial Officer acquired 5,284 shares (option exercise)
  18. 4/A Exercise or conversion Chief Financial Officer acquired 6,000 shares (option exercise)
  19. 4 Open-market sale Chief Technology Officer sold 7,000 shares at an average $27.61 ($193,303)
  20. 4 Derivatives Options or other derivatives

Page 11 of 18 · 351 filings